



04.27-01



UTILITY PATENT APPLICATION TRANSMITTAL

(only for new non-provisional applications under 37 CFR §1.53(b))

Commissioner of Patents Box Patent Application Washington, D.C. 20231 Sir:

Transmitted herewith for filing is the patent application under 37 CFR 1.53(b) of:

AVENTIS DOCKET NO .: CA2413-US NP

INVENTORS: ASTLES, Peter et al.

TITLE: CHEMICAL COMPOUNDS

I hereby certify that this correspondence is deposited with the United States Postal Servi Express Mail in an envelope addresse Commissioner for Patents, Washington, D.C. on

Date of Deposits

Signature

EL608058688US

Express Mail No.

APPLICATION ELEMENTS

1.	Κ.	*Fee Transmittal Form (e.g., PTO/SB/17) (Submit an original and a duplicate for fee processing)	Total Pages 164 Flow) Flications ored R & D (if filed) Total Pages 3 Total Pages 1.63(d)) With Box 16 completed) NVENTOR(S) In attached deleting inventor(s) named in the prior 37 CFR §§ 1.63(d)(2) and 1.33(b).						
2.		Specification (preferred arrangement set forth below) - Descriptive title of the Invention - Cross References to Related Applications - Statement Regarding Fed sponsored R & D - Reference to Microfiche Appendix - Background of the Invention - Brief Summary of the Invention - Brief Description of the Drawings (if filed) - Detailed Description - Claim(s) - Abstract of the Disclosure	Total Pages	164					
3.		Drawing(s) (35 U.S.C. 113)	Total Sheets						
4.	Oatl a.	n or Declaration Newly executed (original or copy) (UNSIG	•	3					
	b.	Copy from a prior application (37 CFR § 1.63(d)) (for continuation/divisional with Box 16 completed)							
		i. <u>DELETION OF INVENTOR(S)</u> Signed statement attached deleting inventor(s) named in the p application, see 37 CFR §§ 1.63(d)(2) and 1.33(b).							
5.		Microfiche Computer Program (Appendix)							
6.	Nuc (if a _i a. b.	cleotide and/or Amino Acid Sequence Submission oplicable, all necessary) Computer Readable Copy Paper Copy (identical to computer copy) Statement verifying identity of above cop							

	· sarmation:
	ed supply the requisite information
if a CONTINUING Application, check appropriate bo	ox, and supres
Continuation, check app. Continuation	ion-in-part
if a CONTINUING A Divisional	-:Fration).
Continuation no, filed	age one of the specification
of prior application no:, filed Group/Art Unit Examiner, Group/Art Unit	No.
of prior application no: Group/Art Unit Examiner (The cross reference has been/will be inserted on page (The cross reference has been	nal Application No.
the benefit of U.S. Provide	on page one of the street declaration from the prior
Group/Art Staminer Group/Art Staminer Group/Art Staminer Group/Art Staminer (The cross reference has been/will be inserted This application claims the benefit of U.S. Provision This application claims the benefit of U.S. Provision Stamon Claims the benefit of U.S. Provision This application the U.S. Provision This application This application the U.S. Provision This application the U.S. Provision This application Th	randivisional and a copy of the design
filed . (The cross	of the oath or declaration and is
aration By Reference (useas:	n which a copy of the accompanying application as
Incorporation is enclosed.)	nal Applied I on page one of the specification): I on page one of the specification): I on page one of the specification from the prior I on page one of the specification from the prior I on page one of the specification and is I on page on
This application claims (The cross reference has been many filled (The cross reference has been many filled (The cross reference has been many filled (Incorporation By Reference (useable if filing a conting application is enclosed.) (Application is	
Supplied Py	
TOUCATION PARTS	
ACCOMPANYING APPLICATION PARTS ASSIgnment Papers (cover sheet & documents) Assignment Papers (sheet & documents)	(s))
	Power of
7. Assignment Papers (*) 37 CFR §3.73(b) Statement 37 CFR §3.73(b) assignee) 38 There is an assignee)	Attorney
7. 37 CFR §3.73(b) State 8. (when there is an assignee) (when there is an assignee) (when there is an assignee)	Copies of IDS
English Transition	Citations
Information District (IDS)/PTO-1449	
10. Landan All (1947)	tion
11 DOCEDO 11-017-011	Statement filed in prior application,
11. Return Receipt Postcard (Minute 12. Should be specifically itemized) (Should be specifically itemized) (Should be specifically itemized)	Statement filed in prior GFT Status still proper and desired
13. PTO/SB/09-12) (PTO/SB/09-12) (PTO/SB/09-12)	5)
Cortified Copy (simed)	licate) 37 CFR § 1.02
(if foreign priority to Table 4 (in due)	ompact Discs
14. German priority is claimed, (if foreign priority is claimed) 15. Other: 1-CDR for Table 4 (in dupled) 2-Transmittal Letter for Co	
	005487
TONDENCE ADDRESS	
CORRESPONDENCE ADDRESS	har code label here)
Customer Number or Bar Code Label	(Insert Customer No. or Attach bar code label here)
Custom	
	William C. Coppola, Reg. No. 41,686 William C. Applicant
	William C. Coppela, Ness Attorney/Agent for Applicant
	Attomeyina
to InC	
Aventis Pharmaceuticals Inc. Aventis Popartment	
Patent Departs 2006 / P.O. Box ood	
Route #202-2007-0800	
Mail Libuc Jarcey 000	
Bridgewater, New Jerson Bridge	

Telephone (908) 231-**4854** Telefax (908) 231-2626

Aventis Docket No. CA2413-US NP

PTO/SB/17 (11-00)

d for use through 10/31/2002. OMB 0651-0032 ark Office: U.S. DEPAPTMENT OF COMMERCE Patent and Trac

Under the Paperwork Reduction Act of 1995, not persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL for FY 2001

Patent fees are subject to annual revision.

TOTAL AMOUNT OF PAYMENT

(\$) 1,726.00

C	omplete if Known	
Application Number	Not yet assigned	
Filing Date	Herewith	
First Named Inventor	ASTLES, Peter et al.	
Examiner Name	Not yet assigned	
Group / Art Unit	Not yet assigned	
Attorney Docket No.	CA2413-US NP	

METHOD OF PAYMENT						FEE CALCULATION (continued)				
1. X The Commissioner is hereby authorized to charge					3. A	DDITIO	NAL FE			
indicated fees and credit any overpayments to:						Large		Small		
Deposit	_				Fee	Entity Fee	Fee	Entity Fee		
Account Number			1	8-1982	Code	(\$)	Code	(\$)	Fee Description	Fee Paid
Deposit Account Aventis Pharmaceuticals Products Inc.						. 20	005	65	Surcharge - late filing fee or oath	
Name	_,L_				105	1 30	205	ŲJ	Surcharge - late provisional filing fee or	
Ŀ		harge Any Ad nder 37 CFR			127	50	227	25	cover sheet Non-English Specification	
	Ar	oplicant c:aim	s small ent		139	130	139	130	Non-English Specification	
		ee 37 CFR 1			147	2,5/20	147	2,520	For filing a request for ree-amination	
2. Payment Enclosed: Check Credit Card Money Order Other					112	920*	112	920*	Requesting publication of SIR prior to Examiner action	
FEE CALCULATION					113	1,840*	113	1,840*	Requesting publication of SIR after Examiner action	
1. BASI	C FII	LING FEI			1		e-=		Extension for roply within first month	
					115 116	110 390	215 ⊋16	55 195	Extension for reply within first month Extension for reply within second month	
	ntity Fee	Small Fee	Entity Fee	Fee Description Fee	110	.,500	2. 10	,,,,		
Code	(\$)	Code	(\$)	Paid	4	890	217	445	Extension for reply within third month	
	710	201	355	Utility filing fee 710	117	390 1,390	217	695	Extension for reply within fourth month	
	320	206	160	Design filing Fee	128	1,890	228	945	Extension for reply within fifth month	
	490	207	245	Plant filing fee	119	310	219	155	Notice of Appeal	
	710	208	355	Reissue filing fee Provisional filing	4		220	155	Filing a brief in support of an appeal	
114	150	214	75	fee	120	310	221	135	Request for oral hearing	
		SUBTO	TAL (1	(\$)710	121	<i>2</i> 70			•	
2. EXTRA CLAIM FEES					138	1,510	138	1,510	Petition to institute a public use proceeding	
				Fee	140	110	240	55	Petition to revive - unavoidable	
			Extra Claims	from Fee below Paid	1					
Total Claims	72	-20**		x 18 = 936	141	1,240	241	620	Petition to revive - unintentional	
Independent	4	- 3**	= 1	x 80 = 80	142	1,240	242	620	Utility issue fee (or reissue)	
Claims	L		L		143	440	243	220	Design issue fee	
Multiple Depe	ndent			270 = 0	144	600	244	300	Plant issue fee	
Multiple Depe	riuciii				122	130	122	130	Petitions to the Commissioner	
	ntity	Small	Entity		123	50	123	50	Petitions related to provisional applications	
Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description	1				.,	
10.3	18	203	9	Claims in excess of 20	126	180	126	180	Submission of Information Disclosure Stmt	
102	80	202	40	Independent claims in excess	581	40	581	40	Recording each patent assignment per	
102				of 3		710	216	355	property (times number of properties) Filing a submission after final rejection	
104	270	204	135	Multiple dependent claim, if not paid	146	710	246	373	(37 ČFR § 1.129(a))	
109	80	209	40	**Reissue independent claims over original patent	149	710	249	355	For each additional invention to be examined (37 CFR § 1.129(b))	
110	18	210	9	**Reissue claims in excess of 20 and over original patent	179	710	279	355	Request for Continued Examination (RCE)	
				20 and over original paterit	169	900	169	900		
		SUBT	OTAL (2) (\$)1016.00	Oth⇔r f	ee (specify)			
**or number previously paid, if greater; For Reissues, see above					*Reduc	ced by Bas	ic Filing Fe	e Paid	SUBTOTAL (3) (\$)	
L		, , ,	J							
SUBMITT	ED B	Y							Complete (If applicable)	
Name (Pr			lliam C	.,Coppola /			stration N		41,686 Telephone (908) 231-	4854

Signature

WARNING:Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S):

ASTLES, ET AL.

EXAMINER:

UNASSIGNED

SERIAL NO.

UNASSIGNED

ART UNIT :

UNASSIGNED

FILED

APRIL 26, 2001

FOR

CHEMICAL COMPOUNDS

CERTIFICATE OF MAILING UNDER 37 CFR 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service as EXPRESS MAIL with label No. EL608058688US in an envelope addressed to the ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, DC 20231 on April 26, 2001.

William C. Coppola, Reg. No. 41,686 (Name of Registered Representative)

(Signature and Date)

TRANSMITTAL LETTER ACCOMPANYING SUBMISSION OF COMPACT DISCS UNDER 37 CFR 1.52

ASSISTANT COMMISSIONER FOR PATENTS WASHINGTON, D.C. 20231

Dear Sir:

Pursuant to 37 CFR 1.52, Applicants submit the instant transmittal letter to accompany two (2) compact discs being filed with the above-identified Application on April 26, 2001. The two enclosed compact discs are identical. In the event that, for some reason, the discs are not identical, the United States Patent and Trademark Office will use the compact disc labeled "Copy 1" for further processing. The following information pertains to both discs:

1. Format for discs: IBM-PC;

2. Operating System for discs: MS-Windows;

3. File on discs: Table 4 of the above-identified Application, filed with the

United States Patent and Trademark Office via Express

mail on April 26, 2001;

4. Size of File on discs: 237 KB; and

5. Creation Date of discs: April 23, 2001.

CONCLUSION

Early and favorable action on the claims is earnestly solicited.

Respectfully submitted,

William C. Coppola

Attorney for Applicant(s) Registration No. 41,686

AVENTIS PHRAMACEUTICALS PRODUCTS INC.

Route 202-206; Mail Stop: EMC-G1

P.O. Box 6800

Bridgewater, NJ 08807